GNI Group Ltd. (TYO:2160)
2,482.00
-85.00 (-3.31%)
At close: Feb 6, 2026
GNI Group Revenue
GNI Group had revenue of 7.10B JPY in the quarter ending September 30, 2025, with 30.16% growth. This brings the company's revenue in the last twelve months to 25.78B, up 13.78% year-over-year. In the year 2024, GNI Group had annual revenue of 23.61B, down -9.22%.
Revenue (ttm)
25.78B
Revenue Growth
+13.78%
P/S Ratio
5.36
Revenue / Employee
29.73M
Employees
867
Market Cap
138.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.61B | -2.40B | -9.22% |
| Dec 31, 2023 | 26.01B | 8.59B | 49.33% |
| Dec 31, 2022 | 17.42B | 4.73B | 37.26% |
| Dec 31, 2021 | 12.69B | 2.92B | 29.85% |
| Dec 31, 2020 | 9.77B | 2.33B | 31.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takara Bio | 44.08B |
| Nxera Pharma | 28.70B |
| PeptiDream | 17.93B |
| RaQualia Pharma | 3.05B |
| Japan Tissue Engineering | 2.26B |
| AnGes | 818.00M |
| Cuorips | 360.00M |
| Healios K.K. | 97.00M |